Los Angeles Capital Management LLC cut its position in Heron Therapeutics, Inc. (NASDAQ:HRTX – Free Report) by 7.6% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 220,834 shares of the biotechnology company’s stock after selling 18,065 shares during the period. Los Angeles Capital Management LLC’s holdings in Heron Therapeutics were worth $439,000 at the end of the most recent quarter.
Several other institutional investors have also recently modified their holdings of the company. Capital Investment Counsel Inc increased its holdings in Heron Therapeutics by 27.2% in the 2nd quarter. Capital Investment Counsel Inc now owns 14,625 shares of the biotechnology company’s stock worth $51,000 after buying an additional 3,125 shares during the period. Price T Rowe Associates Inc. MD increased its stake in shares of Heron Therapeutics by 15.4% in the first quarter. Price T Rowe Associates Inc. MD now owns 29,922 shares of the biotechnology company’s stock worth $83,000 after acquiring an additional 3,991 shares during the period. The Manufacturers Life Insurance Company raised its holdings in shares of Heron Therapeutics by 16.0% during the second quarter. The Manufacturers Life Insurance Company now owns 45,771 shares of the biotechnology company’s stock worth $160,000 after purchasing an additional 6,328 shares during the last quarter. nVerses Capital LLC acquired a new position in Heron Therapeutics during the second quarter valued at $27,000. Finally, Wealth Enhancement Advisory Services LLC boosted its holdings in Heron Therapeutics by 21.2% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 45,273 shares of the biotechnology company’s stock valued at $90,000 after purchasing an additional 7,927 shares during the last quarter. 80.01% of the stock is currently owned by hedge funds and other institutional investors.
Heron Therapeutics Stock Down 4.0 %
NASDAQ:HRTX opened at $1.19 on Friday. Heron Therapeutics, Inc. has a 52 week low of $0.81 and a 52 week high of $3.93. The stock’s 50-day moving average price is $1.82 and its 200-day moving average price is $2.51. The stock has a market capitalization of $180.99 million, a PE ratio of -6.61 and a beta of 1.81.
Wall Street Analyst Weigh In
Several brokerages have recently issued reports on HRTX. StockNews.com raised Heron Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday. Needham & Company LLC lowered their price objective on Heron Therapeutics from $5.00 to $4.00 and set a “buy” rating on the stock in a research report on Wednesday.
View Our Latest Stock Report on HRTX
About Heron Therapeutics
Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Featured Stories
- Five stocks we like better than Heron Therapeutics
- What Are Growth Stocks and Investing in Them
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
- How to Start Investing in Real Estate
- Freeport-McMoRan, Copper Demand Short-Term Pain, Long-Term Gain
- Why Are These Companies Considered Blue Chips?
- Time to Load Up on Home Builders?
Want to see what other hedge funds are holding HRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heron Therapeutics, Inc. (NASDAQ:HRTX – Free Report).
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.